{"id":3853,"date":"2025-05-14T13:37:20","date_gmt":"2025-05-14T10:37:20","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3853"},"modified":"2025-05-14T13:55:46","modified_gmt":"2025-05-14T10:55:46","slug":"satellos-sat-3247-q1-2025-results","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/satellos-sat-3247-q1-2025-results\/","title":{"rendered":"Satellos, SAT-3247 2025 1. \u00c7eyrek Sonu\u00e7lar\u0131n\u0131 Bildiriyor, \u015eirketin Son \u0130lerlemesini ve Gelecek Planlar\u0131n\u0131 Vurguluyor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Satellos Bioscience, bug\u00fcn 31 Mart 2025&#039;te sona eren birinci \u00e7eyre\u011fe ili\u015fkin mali sonu\u00e7lar\u0131n\u0131 ve kurumsal \u00f6nemli noktalar\u0131n\u0131 duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ortak Kurucusu ve \u0130cra Kurulu Ba\u015fkan\u0131 Frank Gleeson, &quot;SAT-3247&#039;nin ilerlemesindeki devam eden ilerlememizden \u00e7ok memnunuz,&quot; dedi. &quot;Yeti\u015fkin DMD hastalar\u0131nda Faz 1b \u00e7al\u0131\u015fmam\u0131zdan elde etti\u011fimiz verileri 2025&#039;in 2. \u00e7eyre\u011finde payla\u015fmay\u0131 planl\u0131yoruz ve bu da bir di\u011fer \u00f6nemli geli\u015ftirme kilometre ta\u015f\u0131n\u0131 i\u015faret ediyor. Bir \u015eirket olarak, bir sonraki b\u00fcy\u00fck geli\u015ftirme ad\u0131m\u0131m\u0131z olarak yeni ilac\u0131m\u0131z\u0131 pediatrik DMD hastalar\u0131nda randomize, plasebo kontroll\u00fc bir Faz 2 POC denemesine ilerletmek i\u00e7in iyi bir konumda oldu\u011fumuza inan\u0131yoruz. Bu \u00e7al\u0131\u015fma, v\u00fccudun hasarl\u0131 veya kay\u0131p kaslar\u0131 onarma ve yenileme yetene\u011fini geri kazand\u0131rmadaki olas\u0131 faydas\u0131n\u0131 ara\u015ft\u0131r\u0131rken, SAT-3247&#039;nin g\u00fcvenli\u011fini \u00f6nemli bir pediatrik pop\u00fclasyonda daha fazla de\u011ferlendirmek \u00fczere tasarlanacakt\u0131r.&quot;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Satellos SAT-3247 1.\u00c7eyrek 2025 Sonu\u00e7lar\u0131<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Duchenne kas distrofisi (DMD) olan yeti\u015fkin hastalarda Faz 1b denemesine kat\u0131l\u0131m tamamland\u0131; veri analizi ve raporlamas\u0131n\u0131n 2025&#039;in 2. \u00e7eyre\u011finde yap\u0131lmas\u0131 bekleniyor<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>D\u00fczenleyici onay al\u0131nd\u0131 ve Faz 1b&#039;deki DMD hastalar\u0131n\u0131n 11 ay daha tedavi edilmesi i\u00e7in uzun vadeli bir takip \u00e7al\u0131\u015fmas\u0131n\u0131n ba\u015flat\u0131lmas\u0131na izin verildi<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Kas Distrofisi Derne\u011fi (MDA) Konferans\u0131nda sunulan SAT-3247 profili, ilac\u0131n sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerde \u00f6ng\u00f6r\u00fclebilir bir farmakokinetik (PK) profile sahip g\u00fcvenli ve iyi tolere edildi\u011fini g\u00f6stermi\u015ftir<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pediatrik DMD hastalar\u0131nda Faz 2 randomize, plasebo kontroll\u00fc klinik kavram kan\u0131t\u0131 (POC) denemesini ba\u015flatmak i\u00e7in onay almak \u00fczere k\u00fcresel d\u00fczenleyici ba\u015fvurular\u0131n 2025&#039;in 3. \u00e7eyre\u011finde sunulmas\u0131 bekleniyor<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Satellos SAT-3247 Klinik \u0130lerleme<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>19 Mart 2025&#039;te Satellos, Dallas, TX&#039;teki MDA Klinik ve Bilimsel Konferans\u0131&#039;nda ilk Faz 1a verilerini sundu. Veriler, SAT-3247&#039;nin hem tek doz hem de tekrarlanan doz uygulamas\u0131ndan sonra g\u00fcvenli, iyi tolere edildi\u011fini ve \u015eirketin klinik \u00f6ncesi PK tahminleriyle tutarl\u0131 oldu\u011funu g\u00f6sterdi. \u2013 <a href=\"https:\/\/dmdwarrior.com\/tr\/satellos-presents-initial-data-from-the-phase-1-trial-of-sat-3247-at-the-2025-muscular-dystrophy-association-clinical-scientific-conference\/\" target=\"_blank\" rel=\"noreferrer noopener\">SAT-3247&#039;nin 1. Faz Denemesinden Veriler<\/a> \u2013<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>10&#039;a kadar yeti\u015fkin DMD hastas\u0131nda Faz 1b denemesi kay\u0131tlar\u0131n\u0131 tamamlad\u0131. \u00c7al\u0131\u015fma, g\u00fcvenli\u011fi, PK&#039;yi ve ke\u015fifsel farmakodinamik belirte\u00e7leri de\u011ferlendirmek i\u00e7in 28 g\u00fcnl\u00fck, a\u00e7\u0131k etiketli bir tasar\u0131md\u0131r.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Satellos&#039;nin 2025&#039;in 2. \u00e7eyre\u011finde analizleri tamamlay\u0131p 1. Faz verilerinin tamam\u0131n\u0131 raporlamas\u0131 bekleniyor.<\/li>\n\n\n\n<li>Faz 1b hastalar\u0131n\u0131n ek 11 ay s\u00fcreyle tedavisine olanak sa\u011flayan uzun vadeli takip klinik \u00e7al\u0131\u015fmas\u0131 Avustralya&#039;da d\u00fczenleyici onay ald\u0131. \u2013 <a href=\"https:\/\/dmdwarrior.com\/tr\/satellos-sat-3247-phase-2-clinical-study-ready-to-launch\/\" target=\"_blank\" rel=\"noreferrer noopener\">Satellos, SAT-3247&#039;nin 2. Faz Klinik \u00c7al\u0131\u015fmas\u0131n\u0131 Ba\u015flatmaya Haz\u0131rlan\u0131yor<\/a> \u2013<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>2025&#039;in 3. \u00e7eyre\u011finde ger\u00e7ekle\u015ftirilmesi planlanan pediatrik DMD hastalar\u0131nda k\u00fcresel Faz 2 randomize, plasebo kontroll\u00fc POC denemesi i\u00e7in onay talep eden d\u00fczenleyici ba\u015fvurular.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Satellos Bioscience, today announced its financial results and corporate highlights for the first quarter ended March 31, 2025. \u201cWe are very pleased with our continued progress in the advancement of SAT-3247,\u201d said Frank Gleeson, Co-founder and Chief Executive Officer. \u201cWe plan to share data from our Phase 1b study in adult DMD patients in Q2 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3854,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[254,251,252,253],"class_list":["post-3853","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-frank-gleeson","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3853"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3853\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3854"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}